Abstract
Background and objective: The SENIORS trial demonstrated that nebivolol is effective in the treatment of heart failure in elderly patients (e.g. ≥70 years). This analysis evaluates the cost effectiveness of nebivolol compared with standard treatment.
Methods: An individual patient-simulation model based on a Markov modelling framework was developed to compare costs and outcomes for nebivolol and standard care in patients with heart failure starting treatment at the age of 70 years. Health states were defined by New York Heart Association (NYHA) class and death. At a given NYHA class and a given cycle, patients could die, be hospitalized for cardiovascular disease or remain stable. Risks for these events were derived from individual patient data from the SENIORS trial. The risk of each event in a given cycle was based on the subject’s baseline characteristics and time in the current health state.
The economic analysis was conducted from the UK NHS perspective with a lifetime horizon. The costs (€; year 2006 values) considered were drug costs for nebivolol and other cardiac drugs, costs of GP visits, outpatient specialist visits and cardiovascular-related hospitalizations. Univariate and probabilistic sensitivity analysis was conducted.
Results: In the baseline analysis, the total cost per patient was €6740 and €9288, and QALYs were 5.194 and 5.843 for patients aged 70 years at the start of treatment for the standard treatment and nebivolol groups, respectively. The probabilistic sensitivity analysis provided an incremental cost-effectiveness ratio of €3926 (95% CI 3731, 4159) per QALY.
Conclusions: This analysis indicates that nebivolol appears to be a cost-effective treatment for elderly patients with heart failure compared with standard care.
References
Ho KK, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993 Oct; 22: 6A-13A
Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart failure. Eur Heart J 1997; 18 (2): 208–25
Cowie MR, Fox KF, Wood DA, et al. Hospitalisation of patients with heart failure: a population-based study. Eur Heart J 2002; 23 (11): 877–85
Stewart S, Jenkins A, Buchan S, et al. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002; 4 (3): 361–71
Hall SA, Cigarroa CG, Marcoux L, et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta adrenergic blockade. J Am Coll Cardiol 1995 Apr; 25 (5): 1154–61
Packer M, Bristow MR, Cohn JN, for the U.S. Carvedilol Heart Failure Study Group, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996 May; 334 (21): 1349–55
The CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 1999 Jan; 353 (9146): 9–13
The MERIT-HF Study Group. Effects of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999 Jun; 353 (9169): 2001–7
Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001 June; 3 (3): 351–7
Flather MD, Shibata MC, Coats AJS, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005 Feb; 26 (3): 215–25
Levy AR, Briggs AH, Demers C, et al. Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. Am Heart J 2001 Sep; 142 (3): 537–43
Cowper PA, DeLong ER, Whellan DJ, et al. Economic effects of beta-blocker therapy in patients with heart failure. Am J Med 2004 Jan; 116 (2): 104–11
Caro JJ, Migliaccio-Walle K, O’Brien JA, MERIT-HF Study Group, et al. Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial. J Card Fail 2005 Dec; 11 (9): 647–56
Vera-Llonch M, Menzin J, Richner RE, et al. Cost-effectiveness results from the US Carvedilol Heart Failure Trials Program. Ann Pharmacother 2001 Jul-Aug; 35 (7–8): 846–51
Delea TE, Vera-Llonch M, Richner RE, et al. Cost effectiveness of carvedilol for heart failure. Am J Cardiol 1999 Mar; 83 (6): 890–6
van Hout BA, Simeon GP, McDonnell J, et al. Economic evaluation of benazepril in chronic renal insufficiency. Kidney Int Suppl 1997 Dec; 63: S159–62
Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimer’s disease: a Markov-cycle evaluation of five years’ therapy using donepezil. Eur Neuropschopharmacol 1998 Nov; 8 (2): 271–271(1)
Roze S, Liens D, Palmer A, et al. A health economic model to determine the long-term costs and clinical outcomes of raising low HDL-cholesterol in the prevention of coronary heart disease. Curr Med Res Opin 2006 Dec; 22 (12): 2549–56
Welsing PM, Severens JL, Hartman M, et al. The initial validation of a Markov model for the economic evaluation of (new) treatments for rheumatoid arthritis. Pharmacoeconomics 2006; 24 (10): 1011–20
Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13 (4): 322–38
Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17 (5): 479–500
Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy 2004 Apr; 9 (2): 110–8
Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006; 15 (12): 1295–310
Yao G, Freemantle N, Calvert MJ, et al. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 2007; 28 (1): 42–51
Government Actuary’s Department. Life tables. London: GAD[online]. Available from URL: http://www.gad.gov.uk/Demography_Data/Life_Tables/ [Accessed 2007 Jan 18]
British national formulary 52[online]. Available from URL: http://www.bnf.org/bnf/ [Accessed 2007 Jan 18]
Curtis L, Netten A, editors. Unit costs of health and social care 2006. Kent: University of Kent, PSSRU, 2006[online]. Available from URL: http://www.pssru.ac.uk/pdf/uc/uc2006/uc2006.pdf [Accessed 2007 Jan 18]
UK National Health Service; Department of Health. The NHS reference costs 2005–06. London: Department of Health[online]. Available from URL: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_062884 [Accessed 2008 Aug 19]
Appleby J, Devlin N, Parkin D. NICE’s cost effectiveness threshold. BMJ 2007 Sep; 335 (7619): 527–8
Acknowledgements
The SENIORS study was sponsored by Menarini Research SpA, Florence, Italy, and the scientific conduct was managed by an independent Steering Committee. Menarini has made the data from the SENIORS study available for the present analysis, which was carried out independently in the Health Care Evaluation Group of the University of Birmingham. A grant for this work was provided by Menarini. The manuscript was reviewed by all authors and was provided to representatives from Menarini for comment in advance of submission for publication.
Guiqing Yao received funding from Menarini for conducting this research. Nick Freemantle has received funding for research, consulting and travel expenses from a number of companies manufacturing drugs and devices for heart failure. Marcus Flather holds a research grant from Menarini and has received speaker fees for presentations at meetings. He also holds research grants and has received speaker fees from the following companies: Astra Zeneca, GSK, sanofi-aventis, Bristol-Myers Squibb, CSL Behring, Eisai and Boehringer Ingelheim. He also holds consultancy contracts with EISAI, CSL Behring, sanofi-aventis and Bristol-Myers Squibb. Philip Poole-Wilson has received funding for research, consulting and travel expenses from companies with an interest in heart failure. He was a principal investigator for SENIORS and for COMET (Carvedilol Or Metoprolol European Trial), both trials relating to the use of β-blockers in heart failure. Andrew Coats has received funding for research, consulting and travel expenses from companies with an interest in heart failure. He was a principal investigator for SENIORS and for COPERNICUS (Carvedilol Prospective Randomized Cumulative Survival), both trials relating to the use of β-blockers in heart failure.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yao, G., Freemantle, N., Flather, M. et al. Long-Term Cost-Effectiveness Analysis of Nebivolol Compared with Standard Care in Elderly Patients with Heart Failure. Pharmacoeconomics 26, 879–889 (2008). https://doi.org/10.2165/00019053-200826100-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200826100-00007